Skip to main content

Rezolute, Inc.

corporate_fare Company Profile

Rezolute, Inc.

RZLT·NASDAQ·Life Sciences·CIK 0001509261

Rezolute, Inc. is a late-stage rare disease company that develops treatments for persistent and severe low blood sugar (hypoglycemia) linked to various forms of hyperinsulinism (HI). The company's primary clinical asset is ersodetug, an intravenously administered human monoclonal antibody. Ersodetug is designed to treat refractory hypoglycemia caused by multiple forms of hyperinsulinism. It works by binding to a specific site on the insulin receptor in insulin-sensitive tissues like the liver, fat, and muscle. This action reduces insulin receptor activity, which helps to normalize glucose levels in conditions where insulin or insulin-like substances (such as IGF-2 variants) are elevated. Ersodetug exhibits dose-dependent pharmacokinetics with a half-life exceeding 2 weeks, suggesting the potential for monthly dosing. The company is developing ersodetug to treat any form of HI, as its mechanism of action, downstream from the source of HI (insulin or IGF-2 production), could make it broadly effective for HI-related hypoglycemia, whether genetic or acquired. In the sunRIZE Phase 3 study for congenital HI, announced on December 11, 2025, ersodetug did not meet its primary endpoint (hypoglycemia events by finger stick self-monitored blood glucose) or its key secondary endpoint (time in hypoglycemia by continuous glucose monitoring) at the Week 24 evaluable window. However, the study consistently showed larger and often nominally statistically significant reductions in hypoglycemia compared to placebo throughout the maintenance dosing phase across various pre-specified and post-hoc CGM-based endpoints.

Rezolute, Inc. (NASDAQ:RZLT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for RZLT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for RZLT spans FWP, 424B5, 8-K, 10-K.

Recent high-impact activity:

  • Rezolute Prices $100M Offering as Lead Drug Hits Phase 3 Efficacy Goal
  • Rezolute Prices $100M Offering at $3.87/Share, Led by Frazier Life Sciences
  • Rezolute Launches Underwritten Stock and Pre-Funded Warrant Offering Days After $400M Shelf
  • Rezolute's upLIFT Phase 3 Hits Primary Endpoint in Tumor Hyperinsulinism
  • Rezolute Launches Underwritten Stock and Pre-Funded Warrant Offering Days After $400M Shelf

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-$77.59M
Diluted EPS
-$0.75
Op. Cash Flow
-$64.64M
Operating Income
-$82.97M
Cash & Equivalents
$10.62M
Debt / Equity
0.00×
Shares Outstanding
96.41M sh
Source: 10-K · filed 2026-09-24 · accession 0001104659-26-110420

Short Interest & Short Volume

14.93 days to cover

FINRA reported short interest of 18,498,517 shares in RZLT as of the October 30, 2026 settlement, a 3.5% decrease from the prior period — about 14.9 days to cover at its recent average daily volume. On November 20, 2026, 49.3% of RZLT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,498,517 shares as of October 30, 2026
Change vs prior period▼ 3.5%
Days to cover14.93 at avg daily volume of 1,239,409
Daily short volume (FINRA facilities)49.3% of 1,078,263 shares on November 20, 2026
5-day average short volume40.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for RZLT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.

1 recent capital raise1 shelf registration

Offering Priced at $3.87 per Share · Dilution Adds ~25.8M Shares

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$3.95 +0.77% today
52-week range · as of 2026-11-13 $1.07 – $11.16
Market cap
$379.18M
Volume
2.5M (1.4× avg)
3-mo avg 1.7M
Live data · 2026-11-22 04:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RZLT - Latest Insights

RZLT
Nov 13, 2026, 12:27 PM EST
Source: Benzinga
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $3.95 info
Change: +$0.145 (+4%) info
Market Cap: $379.177M info
RZLT
Nov 13, 2026, 6:26 AM EST
Filing Type: FWP
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $3.95 info
Change: -$0.240 (-6%) info
Market Cap: $379.177M info
RZLT
Nov 13, 2026, 6:19 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $4.09
Real-time Price: $3.95 info
Change: -$0.140 (-3%) info
Market Cap: $379.177M info
RZLT
Nov 13, 2026, 6:18 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.91
Real-time Price: $3.95 info
Change: +$0.040 (+1%) info
Market Cap: $379.177M info
RZLT
Nov 13, 2026, 6:15 AM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $3.87
Real-time Price: $3.95 info
Change: +$0.080 (+2%) info
Market Cap: $379.177M info
RZLT
Nov 05, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.64
Real-time Price: $3.95 info
Change: +$0.310 (+9%) info
Market Cap: $379.177M info
RZLT
Nov 02, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.92
Real-time Price: $3.95 info
Change: +$0.030 (+0.77%) info
Market Cap: $379.177M info
RZLT
Oct 29, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $3.95 info
Change: -$0.170 (-4%) info
Market Cap: $379.177M info
RZLT
Oct 14, 2026, 5:02 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.28
Real-time Price: $3.95 info
Change: -$0.330 (-8%) info
Market Cap: $379.177M info
RZLT
Oct 05, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.31
Real-time Price: $3.95 info
Change: -$0.360 (-8%) info
Market Cap: $379.177M info
RZLT
Oct 05, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.21
Real-time Price: $3.95 info
Change: -$0.260 (-6%) info
Market Cap: $379.177M info
RZLT
Sep 24, 2026, 4:24 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $3.95 info
Change: +$0.010 (+0.25%) info
Market Cap: $379.177M info
RZLT
Sep 24, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $3.95 info
Change: +$0.010 (+0.25%) info
Market Cap: $379.177M info
RZLT
Sep 24, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $3.95 info
Change: +$0.010 (+0.25%) info
Market Cap: $379.177M info
RZLT
Jun 02, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.68
Real-time Price: $3.95 info
Change: +$0.270 (+7%) info
Market Cap: $379.177M info
RZLT
Jun 02, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.71
Real-time Price: $3.95 info
Change: +$0.2407 (+6%) info
Market Cap: $379.177M info
RZLT
May 12, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $3.95 info
Change: +$0.6265 (+19%) info
Market Cap: $379.177M info
RZLT
May 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.30
Real-time Price: $3.95 info
Change: +$0.650 (+20%) info
Market Cap: $379.177M info
RZLT
May 12, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.30
Real-time Price: $3.95 info
Change: +$0.650 (+20%) info
Market Cap: $379.177M info
RZLT
May 04, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.29
Real-time Price: $3.95 info
Change: +$0.660 (+20%) info
Market Cap: $379.177M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets